WATCH-TAVR is a prospective, multicenter, randomized controlled trial. Only centers with approval for commercial WATCHMAN implantation will be included in this trial. Subjects will be enrolled at up to 25 centers in the United States. There will be up to 400 subjects enrolled, with 200 patients being randomized to TAVR + medical therapy and 200 patients randomized to TAVR+WATCHMAN (150 staged and 50 simultaneous). Patients with AF undergoing commercial TAVR will be enrolled in the trial. All patients will receive anticoagulation with warfarin and aspirin for 6 weeks after the procedure.